NBP NovaBridge Biosciences
Pharmaceutical Preparations · Nasdaq · SEC CIK 1778016 · Fiscal year ends 12/31
Financial factors as of 2023-12-31 (FY2023), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY140.7%
TTM net income YoY44.0%
TTM EPS YoY44.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-11,395.1%
Net margin-32,868.5%
FCF margin-11,528.6%
EBITDA margin-11,319.9%
Returns
ROE-62.9%
ROA-43.3%
ROIC (approx.)—
Asset turnover0.00x
Leverage & solvency
Liabilities / assets34.2%
Debt / equity0.00x
Current ratio5.67x
Interest coverage-706.05x
Cash quality & payout
Operating cash flow / net income0.35x
Accruals ratio-28.1%
Payout ratio—
Capex / revenue25.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $62.91M | $21.77M |
| SG&A expense | $31.36M | $29.66M |
| Operating income | -$94.27M | -$51.43M |
| Pretax income | -$88.34M | -$49.70M |
| Income tax | $0 | $0 |
| Net income | -$46.27M | -$22.23M |
| EBITDA | -$94.20M | -$51.16M |
| EPS (basic) | -0.21 | -0.12 |
| EPS (diluted) | -0.21 | -0.12 |
| Weighted avg. shares (diluted) | 220.26M | 186.73M |
| Balance sheet | ||
| Cash & equivalents | $210.63M | $68.26M |
| Short-term investments | $210,000 | $105.14M |
| Current assets | $217.52M | $176.69M |
| PP&E, net | $140,000 | $201,000 |
| Total assets | $260.52M | $212.68M |
| Current liabilities | $26.89M | $8.45M |
| Total liabilities | $29.58M | $11.52M |
| Shareholders' equity | $230.94M | $201.16M |
| Shares outstanding | 265.38M | 187.45M |
| Cash flow statement | ||
| Operating cash flow | -$20.60M | -$52.67M |
| Capital expenditure | $7,000 | $48,000 |
| Free cash flow | -$20.60M | -$52.72M |
| Investing cash flow | $104.97M | -$136.01M |
| Financing cash flow | $57.73M | -$335,000 |
| Depreciation & amortization | $68,000 | $261,000 |
| Stock-based compensation | $5.97M | -$1.95M |
Free plan shows the latest 2 periods; Pro shows all 10 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.